|
Video: What is a Stock Split?
|
|
Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA (lumateperone) has been approved for the treatment of schizophrenia in adults. Co. is developing ITI-1284, an oral disintegrating tablet for sublingual administration for the treatment of behavioral disturbances in patients with dementia and dementia-related psychosis and for the treatment of certain depressive disorders in the elderly. According to our Intra-Cellular Therapies stock split history records, Intra-Cellular Therapies has had 0 splits. | |
|
Intra-Cellular Therapies (ITCI) has 0 splits in our Intra-Cellular Therapies stock split history database.
Looking at the Intra-Cellular Therapies stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Intra-Cellular Therapies shares, starting with a $10,000 purchase of ITCI, presented on a split-history-adjusted basis factoring in the complete Intra-Cellular Therapies stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$19.00 |
|
End price/share: |
$69.20 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
264.21% |
|
Average Annual Total Return: |
13.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$36,414.04 |
|
Years: |
10.00 |
|
|
|
|
|